Monoclonal antibody A5B7-cisplatin conjugate

Drug Profile

Monoclonal antibody A5B7-cisplatin conjugate

Alternative Names: Anti-CEA monoclonal antibody A5B7-cisplatin conjugate

Latest Information Update: 30 Mar 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biodynamics Research; GlaxoSmithKline; Pharmacia Corporation
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 25 Jan 2001 No-Development-Reported for Cancer in England (Parenteral)
  • 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
  • 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top